Tibotec Pharmaceuticals and Gilead Sciences Inc. (NASDAQ:GILD) agreed to develop and commercialize a fixed-dose HIV treatment combining Tibotec's marketed Prezista darunavir and Gilead's investigational
Read the full 246 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury